# FDA Approves Hikma's Generic Drug Application Hikma Pharmaceuticals received FDA approval for ANDA 220562 on May 29, 2026, expanding its generic drug portfolio and positioning the company to capture additional market share in the competitive generics sector. The approval strengthens Hikma's competitive standing and is expected to contribute to its revenue growth through increased generic medication penetration.